Curated News: National Institute of Allergy and Infectious Diseases (NIAID)

Filters close
Newswise: Tulane University awarded $10.3 million to test therapeutics, vaccines for novel coronavirus
Released: 6-Apr-2020 8:55 AM EDT
Tulane University awarded $10.3 million to test therapeutics, vaccines for novel coronavirus
Tulane University

The National Institutes of Health has awarded Tulane National Primate Research Center a contract of up to $10.3 million to evaluate vaccines and treatments to combat coronavirus disease 2019.

Released: 3-Apr-2020 12:45 PM EDT
Trial for Potential Coronavirus Treatment is Underway at Montefiore and Einstein
Albert Einstein College of Medicine

Montefiore Health System and Albert Einstein College of Medicine has joined a clinical trial to evaluate the experimental drug remdesivir to treat people who are hospitalized with severe COVID-19 infection.

Released: 25-Mar-2020 4:25 PM EDT
COVID-19 Immunotherapy Collab at UGA with Biotech Firm CEL-SCI to Fight Coronavirus
Newswise

CEL-SCI’s immunotherapy candidate aims to treat patients at highest risk of dying from COVID-19. LEAPS immunotherapy has been used in collaboration with the National Institutes for Allergies and Infectious Diseases (NIAID) against another respiratory virus, H1N1, involved in the 2009 H1N1 flu pandemic. Those successful studies demonstrated that LEAPS peptides, given after virus infection has occurred, reduced morbidity and mortality in mice infected with H1N1.

Released: 24-Mar-2020 2:50 PM EDT
UC San Diego Health Launches Clinical Trial to Assess Antiviral Drug for COVID-19
University of California San Diego Health

Researchers at four University of California Health medical centers have begun recruiting participants for a Phase II clinical trial to investigate the safety and efficacy of treating adult patients with COVID-19 with remdesivir, a drug that has shown promising activity against multiple viruses.

Released: 23-Mar-2020 9:30 AM EDT
CEL-SCI to Develop LEAPS COVID-19 Immunotherapy in Collaboration with University of Georgia Center for Vaccines and Immunology
Cel-Sci Corp

Initial studies with COVID-19 coronavirus aim to replicate prior successful preclinical experiments of LEAPS against H1N1pandemic flu in mice conducted with National Institutes for Allergies and Infectious Diseases (NIAID)

Newswise: Breast milk may help prevent sepsis in preemies
Released: 16-Mar-2020 3:45 PM EDT
Breast milk may help prevent sepsis in preemies
Washington University in St. Louis

Researchers at Washington University School of Medicine in St. Louis and Mayo Clinic in Rochester, Minn., have found — in newborn mice — that a component of breast milk may help protect premature babies from developing life-threatening sepsis.

Newswise: Mimicking Cancer’s Evasive Tactics, Microparticles Show Promise Against Transplant Rejection
8-Mar-2020 9:00 PM EDT
Mimicking Cancer’s Evasive Tactics, Microparticles Show Promise Against Transplant Rejection
Health Sciences at the University of Pittsburgh

Inspired by a tactic cancer cells use to evade the immune system, University of Pittsburgh researchers have engineered tiny particles that can trick the body into accepting transplanted tissue as its own, while leaving the immune system intact.

Newswise: LJI scientists identify potential targets for immune responses to novel coronavirus
Released: 11-Mar-2020 6:15 PM EDT
LJI scientists identify potential targets for immune responses to novel coronavirus
La Jolla Institute for Immunology

Publishing in the March 16, 2020, online issue of Host, Cell and Microbe, a team of researchers at La Jolla Institute for Immunology, in collaboration with researchers at the J. Craig Venter Institute, provides the first analysis of potential targets for effective immune responses against the novel coronavirus. The researchers used existing data from known coronaviruses to predict which parts of SARS-CoV-2 are capable of activating the human immune system.

6-Mar-2020 8:30 AM EST
New Study on Covid-19 Estimates 5.1 Days for Incubation Period
Johns Hopkins Bloomberg School of Public Health

An analysis of publicly available data on infections from the new coronavirus, SARS-CoV-2, that causes the respiratory illness COVID-19 yielded an estimate of 5.1 days for the median disease incubation period, according to a new study led by researchers at Johns Hopkins Bloomberg School of Public Health.

Newswise: Bifunctional nanobodies proven effective at protecting against botulinum neurotoxins including Botox
Released: 27-Feb-2020 8:35 AM EST
Bifunctional nanobodies proven effective at protecting against botulinum neurotoxins including Botox
University of California, Irvine

New study reveals potential for developing novel antibody-based antitoxins against botulinum neurotoxins (BoNTs), including the most commonly used, yet most toxic one, Botox.


Showing results

110 of 10

close
0.49995